Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Pizzolitto

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Future Oncology (London, England)|March 10, 2018
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiformeLorena Gurrieri, Elisa De Carlo, Lorenzo Gerratana, et al.
Future Oncology (London, England)|March 13, 2018
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapyElena Ongaro, Lorenzo Gerratana, Marika Cinausero, et al.
Clinical Endocrinology|September 6, 2012
A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytomaAngela V D'Elia, Franco Grimaldi, Stefano Pizzolitto, et al.
Clinical Endocrinology|December 31, 2009
A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterizationMaria D Castellone, Antonella Verrienti, Deva Magendra Rao, et al.
Neuro-Oncology|October 15, 2021
IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroupsRoberta Rudà, Francesco Bruno, Tamara Ius, et al.
Future Oncology (London, England)|February 17, 2015
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancerLuisa Foltran, Giovanna De Maglio, Nicoletta Pella, et al.
The Oncologist|February 20, 2019
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?Enrico Franceschi, Alicia Tosoni, Dario De Biase, et al.
Neuro-Oncology|February 20, 2010
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implicationsAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
The American Journal of Surgical Pathology|February 28, 2008
Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissueRoberto Tirabosco, D Chas Mangham, Andrew E Rosenberg, et al.
Cancers|May 28, 2022
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudyMario Caccese, Matteo Simonelli, Veronica Villani, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Future Oncology (London, England)|March 10, 2018
MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiformeLorena Gurrieri, Elisa De Carlo, Lorenzo Gerratana, et al.
Future Oncology (London, England)|March 13, 2018
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapyElena Ongaro, Lorenzo Gerratana, Marika Cinausero, et al.
Clinical Endocrinology|September 6, 2012
A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytomaAngela V D'Elia, Franco Grimaldi, Stefano Pizzolitto, et al.
Clinical Endocrinology|December 31, 2009
A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterizationMaria D Castellone, Antonella Verrienti, Deva Magendra Rao, et al.
Neuro-Oncology|October 15, 2021
IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroupsRoberta Rudà, Francesco Bruno, Tamara Ius, et al.
Future Oncology (London, England)|February 17, 2015
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancerLuisa Foltran, Giovanna De Maglio, Nicoletta Pella, et al.
The Oncologist|February 20, 2019
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?Enrico Franceschi, Alicia Tosoni, Dario De Biase, et al.
Neuro-Oncology|February 20, 2010
O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implicationsAlba A Brandes, Enrico Franceschi, Alicia Tosoni, et al.
The American Journal of Surgical Pathology|February 28, 2008
Brachyury expression in extra-axial skeletal and soft tissue chordomas: a marker that distinguishes chordoma from mixed tumor/myoepithelioma/parachordoma in soft tissueRoberto Tirabosco, D Chas Mangham, Andrew E Rosenberg, et al.
Cancers|May 28, 2022
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudyMario Caccese, Matteo Simonelli, Veronica Villani, et al.
Pageof 9